Internal Neuromodulation Devices Market By Product (Spinal Cord Stimulators, Deep Brain Stimulators, Sacral and Tibial Neuromodulation Devices, Vagus Nerve and Responsive Neurostimulation Systems, Hypoglossal Nerve Stimulators); By Application (Chronic Pain, Parkinson Disease and Movement Disorders, Epilepsy, Urinary and Fecal Dysfunction, Obstructive Sleep Apnea); By End User (Hospitals, Ambulatory Surgical Centers, Neurology Clinics, Pain Management Clinics, Specialty Urology and Sleep Centers); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Segment Revenue Estimation, Forecast, 2026–2032

The Internal Neuromodulation Devices Market Is Getting a Stronger Commercial Signal

Acquisitions, adaptive implants and new treatment pathways are expanding the commercial scope of neuromodulation, although patient selection, specialist capacity and reimbursement continue to control adoption.

 

Key Points

• The Global Internal Neuromodulation Devices Market is valued at USD 7.8 billion in 2025 and is projected to reach USD 14.3 billion by 2032, expanding at a CAGR of 9.0%, according to Strategic Market Research.

• Spinal cord stimulation was estimated as a USD 2.4 billion global market in 2023, with the United States contributing approximately 80% of revenue.

• Boston Scientific’s USD 3.7 billion Axonics acquisition, Globus Medical’s purchase of Nevro and new Medtronic approvals show that companies are positioning for implant, replacement, programming and data-service revenue.

The market for implantable neuromodulation devices is moving beyond a collection of highly specialized therapies and becoming a broader medical-device platform built around patients who have exhausted conventional care.

That shift is visible in recent acquisitions and approvals. Boston Scientific completed its USD 3.7 billion equity-value acquisition of sacral neuromodulation company Axonics in November 2024. Globus Medical acquired spinal cord stimulation specialist Nevro in an all-cash transaction valued at approximately USD 250 million in April 2025. Medtronic received U.S. approval for adaptive deep brain stimulation in February 2025 and its Altaviva implantable tibial neuromodulation system in September 2025.

These developments do not mean every patient with chronic pain, Parkinson disease, epilepsy, urinary dysfunction or sleep apnea will progress to implantation. Commercial opportunity is concentrated among people with persistent symptoms, documented treatment failure, surgical suitability and access to trained implanting physicians.

Internal neuromodulation includes spinal cord and dorsal root ganglion stimulators, deep brain stimulation systems, sacral and tibial neuromodulation implants, vagus nerve stimulators, responsive neurostimulation systems, hypoglossal nerve stimulators, gastric electrical stimulators and emerging neuroimmune implants.

The business model extends beyond the first operation. Companies generate revenue from trials, pulse generators, leads, electrodes, programming systems, replacement batteries, revisions, remote review and generator replacement. A growing installed base therefore creates recurring demand even when new-patient procedure growth varies.

 

A Large Patient Pool, but a Narrow Commercial Funnel

Chronic pain provides the broadest patient pathway for internal neuromodulation. In 2023, 24.3% of U.S. adults reported chronic pain and 8.5% reported high-impact chronic pain that frequently restricted daily activities.

Only a fraction of that population is considered for spinal cord stimulation or dorsal root ganglion stimulation. Candidates generally reach implantation after medication, rehabilitation, injections or surgery fail to provide sufficient relief. A temporary stimulation trial is commonly used before permanent implantation.

Nevro estimated the global spinal cord stimulation market at approximately USD 2.4 billion in 2023, with the United States contributing about 80%, or roughly USD 1.9 billion. The company also estimated that the addressable U.S. trunk-and-limb chronic-pain population was only around 11% penetrated.

That low penetration indicates substantial clinical headroom, but conversion depends on physician referrals, payer approval and successful trials. Alternative minimally invasive spine procedures can also reach patients earlier and delay progression to spinal cord stimulation.

Nevro generated USD 408.5 million in worldwide revenue in 2024, down 3.9% from USD 425.2 million in 2023. U.S. revenue was USD 353.1 million, accounting for approximately 86.4% of total revenue. Fourth-quarter U.S. permanent implants declined 7.0% and trial procedures fell 14.2%, showing how lower referral and trial activity can quickly affect sales.

Globus Medical’s acquisition of Nevro added high-frequency spinal cord stimulation to a broader musculoskeletal business and gave Globus access to an established pain-specialist network.

Pelvic health is developing through a similar installed-base model. Sacral neuromodulation is used for selected patients with overactive bladder, urge urinary incontinence, non-obstructive urinary retention and fecal incontinence after conservative treatment fails.

Medtronic has reported more than 425,000 cumulative InterStim patients worldwide. That installed base supports programming, revision and generator-replacement revenue in addition to new procedures.

Boston Scientific’s acquisition of Axonics placed a rechargeable sacral neuromodulation platform inside a larger urology portfolio. Medtronic’s Altaviva approval created another implanted route for urge urinary incontinence, using placement near the ankle rather than conventional sacral implantation.

 

Sleep Apnea Creates a Specialist Network Around One Implant

Hypoglossal nerve stimulation has built one of the clearest indication-specific commercial models in neuromodulation. It is used for selected patients with moderate-to-severe obstructive sleep apnea who cannot tolerate or do not benefit adequately from positive-airway-pressure therapy.

A global analysis estimated that 936 million adults aged 30 to 69 had mild-to-severe obstructive sleep apnea, including 425 million with moderate-to-severe disease. The implantable population is considerably smaller because patients must pass anatomical, clinical, surgical and payer assessments.

Inspire Medical Systems reported more than 100,000 cumulative implanted patients by October 2025 and had 1,435 U.S. implanting centers at the end of 2024.

Inspire generated USD 912.0 million in 2025 revenue, increasing 14% from 2024. Fourth-quarter revenue rose 12% to USD 269.1 million, while full-year gross margin reached 85.4%.

The company’s 14% growth exceeded the overall neuromodulation market’s projected 9.0% CAGR, indicating that hypoglossal stimulation is expanding faster than the broader category. Inspire projected 2026 revenue growth of 4% to 10%, however, reflecting reimbursement and coding pressures that may slow conversion.

The segment’s commercial strength depends on connected referral pathways linking sleep physicians, diagnostic laboratories, surgeons and follow-up teams. Center activation can therefore matter as much as product changes.

 

Brain Implants Bring Lower Volumes and Higher Data Value

Deep brain stimulation serves a more selected population than pain or pelvic neuromodulation. More than 1.1 million people in the United States are estimated to live with Parkinson disease, with nearly 90,000 new diagnoses each year. Only a smaller group has the medication response, cognitive profile and surgical suitability required for DBS.

A U.S. National Inpatient Sample analysis identified 7,625 hospitalizations involving DBS lead implantation in 2019 and 6,715 in 2020. The pandemic-affected 2020 total was approximately 11.9% lower.

Medtronic’s BrainSense Adaptive DBS approval in February 2025 marked a competitive shift. The system uses detected brain signals to adjust stimulation rather than relying entirely on fixed programming. This moves competition toward sensing, software and therapy management.

Epilepsy neuromodulation follows an even more data-centered model. Vagus nerve stimulation, responsive neurostimulation and anterior-thalamic DBS serve different drug-resistant epilepsy groups. Approximately 2.9 million U.S. adults and 456,000 children had active epilepsy during recent CDC measurement periods, while around 1.5 million community-dwelling adults reported uncontrolled seizures.

More than 8,000 patients had received the NeuroPace RNS System by the end of 2025. Installed devices had generated more than 22 million intracranial EEG records, giving clinicians continuing information for programming and review.

NeuroPace reported USD 81.7 million in RNS System revenue in 2025, an increase of 25% from 2024. RNS represented 81.7% of the company’s USD 100.0 million total revenue. Fourth-quarter RNS revenue increased 26% to USD 22.4 million, while first-quarter 2026 revenue rose 19.5% year over year to USD 21.7 million.

LivaNova provides a larger benchmark for vagus nerve stimulation. Its neuromodulation segment generated USD 592.8 million in 2025, increasing 7.0% on a reported basis and 6.6% at constant currency. Neuromodulation contributed approximately 42.7% of the company’s USD 1.39 billion total revenue.

The United States generated USD 463.6 million, or 78.2% of LivaNova’s neuromodulation revenue. Europe contributed USD 65.0 million, or 11.0%, while other international markets accounted for USD 64.2 million, or 10.8%. Europe recorded the fastest growth at 18.4%, compared with 5.1% in the United States and 10.1% in other markets.

These results show how narrow implant categories can scale through long-term patient management. They also explain why data-enabled platforms may create switching barriers once physicians and patients are connected to a specific programming system.

 

New Indications Are Testing How Far the Market Can Expand

Neuromodulation is moving into clinical areas where an implant must compete with established pharmaceutical or rehabilitation pathways.

The Vivistim System stimulates the vagus nerve during rehabilitation for selected chronic ischemic-stroke patients with moderate-to-severe arm impairment. Its commercial value depends on coordinated rehabilitation because implantation alone is insufficient.

SetPoint Medical entered a different market when the FDA approved its system in July 2025 for adults with moderately to severely active rheumatoid arthritis after inadequate response or intolerance to at least one biologic or targeted synthetic therapy.

The approval created an implant-based neuroimmune pathway inside a market dominated by oral and injectable drugs. Adoption will depend on whether rheumatologists, payers and patients view a surgical intervention as economically and clinically justified after advanced drug failure.

Gastric electrical stimulation for refractory gastroparesis, VNS for treatment-resistant depression and DBS for severe obsessive-compulsive disorder or dystonia also contribute to the market. Their commercial use is narrower because eligibility is strict and specialist networks are limited.

 

Segmentation Key Highlights

By device type, spinal cord stimulation is among the largest established segments, supported by a USD 2.4 billion global market in 2023 and approximately 80% U.S. revenue concentration. Hypoglossal nerve stimulation is expanding faster, with Inspire’s revenue growing 14% to USD 912.0 million in 2025. Responsive neurostimulation generated USD 81.7 million and grew 25%, while LivaNova’s more mature VNS business produced USD 592.8 million and grew 7.0%.

By application, chronic pain provides the broadest conversion pathway, followed by pelvic-health conditions and obstructive sleep apnea. Parkinson disease, essential tremor and epilepsy support high-value but more selective brain-implant procedures. Stroke rehabilitation, gastroparesis, depression and rheumatoid arthritis represent smaller emerging applications.

By end user, hospitals handle complex brain and multistage procedures, while ambulatory surgical centers are increasingly relevant for pain, pelvic and peripheral-nerve implants. Inspire’s 1,435 U.S. implanting centers show how treatment-network expansion supports an indication-specific platform.

By geography, North America is the most developed market. The United States represented approximately 80% of global spinal cord stimulation revenue and 78.2% of LivaNova’s 2025 neuromodulation revenue. Europe is smaller but recorded 18.4% growth in LivaNova’s business, compared with 5.1% in the United States.

By revenue source, permanent implants generate the largest immediate transaction value, while trials, replacement generators, leads, programming, revisions and remote review support recurring revenue. Installed bases of more than 425,000 InterStim patients, 100,000 Inspire patients and 8,000 RNS patients are increasing the value of post-implant services.

 

Reimbursement and Center Capacity Decide Which Approvals Become Revenue

Regulatory approval creates a possible market, but payer requirements commonly include documented treatment failure, specialist assessment and evidence of benefit from a temporary trial where applicable.

Hospitals and ambulatory surgical centers also evaluate operating-room time, training, inventory, complication risk and follow-up requirements. A higher-priced implant may still be commercially attractive when it reduces revisions, programming burden or long-term service costs.

North America has the most developed infrastructure, supported by multiple approved indications and established reimbursement pathways. Europe has established programs but country-level differences in hospital purchasing and reimbursement. Asia-Pacific contains large pain, Parkinson disease, epilepsy and sleep-apnea populations, although adoption depends on specialist availability, affordability and follow-up access.

The competitive field combines diversified medtech companies and focused specialists. Medtronic participates across pain, DBS, sacral and tibial neuromodulation. Abbott and Boston Scientific compete in pain and brain stimulation, while Boston Scientific added pelvic neuromodulation through Axonics. Globus Medical added Nevro’s USD 408.5 million revenue platform.

LivaNova generated USD 592.8 million from neuromodulation in 2025, NeuroPace generated USD 81.7 million from RNS and Inspire generated USD 912.0 million from hypoglossal stimulation. These figures are company or platform revenues rather than directly comparable total-market shares, but they show where commercial scale is concentrated.

 

What the 9% Forecast Is Signaling

The market is projected to increase from USD 7.8 billion in 2025 to USD 14.3 billion by 2032, representing a 9.0% CAGR, an absolute increase of USD 6.5 billion and cumulative growth of approximately 83.3%.

The strongest procedure-growth routes are likely to come from chronic pain, pelvic neuromodulation and hypoglossal nerve stimulation because they address relatively broad refractory populations through expanding specialist networks.

Inspire’s 14% revenue growth and NeuroPace’s 25% RNS growth in 2025 show that selected subsegments can outperform the broader market, while LivaNova’s 7.0% neuromodulation growth reflects a larger and more mature VNS business.

DBS, RNS and other brain implants will contribute high-value procedures but face tighter patient selection and limited surgical capacity. Adaptive stimulation, sensing and remote review can increase the value generated from each implanted patient.

High procedure costs, specialist shortages, payer delays, surgical risks, infections, lead migration and revision requirements can reduce conversion. Medication, rehabilitation, ablation, conventional surgery and non-invasive devices also remain competing pathways.

The market’s 9.0% growth rate is therefore less a measure of total disease prevalence than of how many treatment-resistant patients reach implant evaluation, obtain authorization and stay connected to a device platform over several years.

 

Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 7.8 Billion
Revenue Forecast in 2032	USD 14.3 Billion
Overall Growth Rate	CAGR of 9.0% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product, By Application, By End User, By Geography
By Product	Spinal Cord Stimulators, Deep Brain Stimulators, Sacral and Tibial Neuromodulation Devices, Vagus Nerve and Responsive Neurostimulation Systems, Hypoglossal Nerve Stimulators
By Application	Chronic Pain, Parkinson Disease and Movement Disorders, Epilepsy, Urinary and Fecal Dysfunction, Obstructive Sleep Apnea
By End User	Hospitals, Ambulatory Surgical Centers, Neurology Clinics, Pain Management Clinics, Specialty Urology and Sleep Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising prevalence of chronic pain and neurological disorders, broader clinical use of implantable neuromodulation therapies, innovation in rechargeable and responsive stimulation systems, and expanding treatment applications across epilepsy, urinary dysfunction, and obstructive sleep apnea
Customization Option	Available upon request